<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349893</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT02349893</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study</brief_title>
  <official_title>Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olympus Surgical Technologies Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olympus Surgical Technologies Europe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The United States is currently experiencing an increase in the incidence and prevalence of&#xD;
      obstructive sleep apnea (OSA). With prevalence in middle-aged adults of 2 to 4% of the&#xD;
      population, untreated OSA has been implicated in increased risk for cardiovascular disease,&#xD;
      including hypertension and heart failure, daytime sleepiness, and increased risk of motor&#xD;
      vehicle accidents.&#xD;
&#xD;
      This study was design in order to evaluate the CelonProSleep plus for multi-level&#xD;
      radiofrequency ablation (RFA) of the palate and base of tongue as a treatment for mild to&#xD;
      moderate obstructive sleep apnea syndrome (OSAS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to demonstrate a clinically significant reduction of obstructive sleep apnea at 12-Month follow-up.</measure>
    <time_frame>12 months following last treatment</time_frame>
    <description>The primary endpoint is the reduction in the apnea hypopnea index (AHI). The objective is to demonstrate at least a 50% responder rate at the 12-Month follow-up visit. A responder to the radiofrequency treatment is defined as a subject with at least a 50% reduction of their AHI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Apnea, Sleep</condition>
  <arm_group>
    <arm_group_label>RFA treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RFA treatment performed with CelonProSleep plus device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RFA treatment</intervention_name>
    <description>RFA treatment using CelonProSleep plus system</description>
    <arm_group_label>RFA treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (≥ 22 years)&#xD;
&#xD;
          -  Self-report of daytime somnolence&#xD;
&#xD;
          -  Body mass index (BMI) ≤ 32&#xD;
&#xD;
          -  Mild to moderate obstructive sleep apnea (AHI 10 - 30; lowest O2 sat ≥ 80%)&#xD;
&#xD;
          -  Evidence of palate and tongue base collapse on supine fiberoptic examination&#xD;
&#xD;
          -  Non-compliant with or refusal of continuous positive airway pressure therapy (CPAP) (&lt;&#xD;
             4 hours per night by patient report)&#xD;
&#xD;
          -  No prior surgical treatment for OSAS other than nasal surgery&#xD;
&#xD;
          -  Willing and capable of providing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another significant sleep disorder (e.g., insomnia, periodic limb movement)&#xD;
&#xD;
          -  Tonsillar hypertrophy&#xD;
&#xD;
          -  Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
          -  Interstitial Lung Disease (ILD)&#xD;
&#xD;
          -  Cystic Fibrosis&#xD;
&#xD;
          -  Acute Repiratory Distress Syndrome (ARDS)&#xD;
&#xD;
          -  Nasal or supraglottic obstruction on fiberoptic examination&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) class III ,IV, V&#xD;
&#xD;
          -  Latex allergy&#xD;
&#xD;
          -  Lidocaine allergy&#xD;
&#xD;
          -  Pregnancy or plans to become pregnant Note: women of childbearing potential must&#xD;
             demonstrate a negative pregnancy test upon enrollment; those patients qualified to&#xD;
             progress to RFA must also demonstrate a negative pregnancy test within 7 days prior to&#xD;
             the date of RFA procedure.&#xD;
&#xD;
          -  Major depression or non-stabilized psychiatric disorder&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Previous palatal or tongue surgery&#xD;
&#xD;
          -  Stable or unstable angina&#xD;
&#xD;
          -  congestive heart failure (CHF)&#xD;
&#xD;
          -  moderate or severe valvular disease&#xD;
&#xD;
          -  transient ischemic attack (TIA)/cardiovascular accident (CVA)&#xD;
&#xD;
          -  Carotid stenosis or endarterectomy&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Room air oxygen saturation (SpO2) &lt; 95%&#xD;
&#xD;
          -  Pulmonary hypertension&#xD;
&#xD;
          -  Dialysis&#xD;
&#xD;
          -  Central or mixed apnea ≥ 10% of respiratory events&#xD;
&#xD;
          -  Participation in another clinical study (enrolled in any concurrent study) whose&#xD;
             investigational plan is judged to interfere or affect any of the measures of this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaun Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Otolaryngology Colorado</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluesleep clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutional Review Board for Human Research (IRB)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-8570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 24, 2015</study_first_submitted>
  <study_first_submitted_qc>January 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

